Compare Citius Pharmaceuticals Inc (CTXR) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs KB Financial Group, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while KB Financial Group, Inc. trades at $121.04 (market cap $41.53B). The key difference: KB Financial Group, Inc. is far larger — about 2836.7× Citius Pharmaceuticals Inc's market cap, and KB Financial Group, Inc. pays a 2.6% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | KB | |
|---|---|---|
Market Cap | $14.64M | $41.53B |
Sector | Health | Financials |
52-Week High | $1.82 | $123.25 |
52-Week Low | $0.53 | $77.50 |
Enterprise Value | $10.86M | — |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
KB Financial Group (KB) trades at $123.25, up 0.05% with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, 27.82% net income margin, and 27.47% profit margin in 2025. Recent news highlights expansion into non-banking segments and dividend potential. Revenue grew to $21.23T in 2025, with net income reaching $5.83T.
The outlook remains positive with earnings growth and diversification driving upside, though technical oscillators signal overbought conditions. Risks include volatile cash flows and competitive pressures. Analyst consensus is mixed with 33% buy ratings. The stock presents value with a P/E of 11.84 but requires monitoring of execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
